Atezolizumab plus bevacizumab was recently approved as first-line systemic therapy for patients with advanced HCC. Read an expert’s thoughts how this new approach will fit into contemporary treatment paradigms.
When should patients with HCC be transitioned from locoregional to systemic therapy to maximize therapeutic benefit? In this commentary, HCC expert Richard Finn, MD, provides his thoughts on this important question.
Review expert insights into the selection of optimal systemic treatment for patients with advanced HCC and Child-Pugh B liver disease.